# US 2013/0259870 A1 · Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259870 A1
- Document ID: US20130259870A1
- Status: Published application
- Kind: A1
- Application number: 13/573,436
- Filed: 2012-09-14
- Published: 2013-10-03
- Earliest claimed: 2011-09-16
- Assignees: Galectin Therapeutics, Inc.
- Inventors: Peter G. Traber; Eliezer Zomer; Anatole A. Klyosov
- Web page: https://patentgrep.com/patent/US20130259870A1

## CPC

- C08B 37/0045: {alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof}
- A61K 31/732: Pectin
- A61K 31/736: Glucomannans or galactomannans, e.g. locust bean gum, guar gum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C08B 37/006: {Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof}
- C08B 37/0087: {Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof}
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Aspects of the invention provides provide methods for treatment of NASH and associated liver fibrosis. In particular, aspects of the invention relate to the therapeutic formulation comprising a galactomannan polysaccharide compound for the treatment of NASH and associated liver fibrosis.

## Claims

### Claim 1

A method comprising the steps of:
obtaining a composition for parenteral or enteral administration comprising a galactomannan polysaccharide in an acceptable pharmaceutical carrier;
administering to a subject in need thereof an effective dose of the composition, wherein administration results in at least one of the following:
reduction of at least one point in severity of nonalcoholic fatty liver disease or nonalcoholic steatohepatitis grading scoring systems, reduction of the level of serum markers of nonalcoholic steatohepatitis activity, reduction of nonalcoholic steatohepatitis disease activity or reduction in the medical consequences of nonalcoholic steatohepatitis,
wherein the subject has at least one of the following: fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, or nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma.

### Claim 2 (depends on 1)

The method of claim 1 wherein administration results in reduction of the accumulation of fat in the liver by at least 10%.

### Claim 3 (depends on 1)

The method of claim 1 wherein administration results in reduction of the accumulation of fat in the liver as assessed in percentage of hepatocytes with fat in the liver.

### Claim 4 (depends on 3)

The method of claim 3 wherein the reduction in the accumulation of fat in the liver is assessed by ultrasound or magnetic resonance imaging protocols.

### Claim 5 (depends on 1)

The method of claim 1 wherein administration results in reduction of the hepatocyte ballooning by at least 10%.

### Claim 6 (depends on 5)

The method of claim 5 wherein the reduction of hepatocyte ballooning is assessed in percentage of swollen hepatocytes.

### Claim 7 (depends on 1)

The method of claim 1 wherein administration results in reduction of infiltration of neutrophils and lymphocytes by at least 10% in portal, central and lobular areas of a liver specimen.

### Claim 8 (depends on 1)

The method of claim 1 wherein administration results in reduction of accumulation of collagen in the liver by at least 5%.

### Claim 9 (depends on 8)

The method of claim 8 wherein the reduction of the accumulation of collagen in the liver is determined non-invasively by tissue stiffness/elasticity measurement using ultrasound or magnetic resonance elastography.

### Claim 10 (depends on 1)

The method of claim 1 wherein the serum markers of nonalcoholic steatohepatitis activity are selected from the group consisting of transaminases, coenzyme Q reduced or oxidized, or a combination thereof.

### Claim 11 (depends on 1)

The method of claim 1 wherein the reduction of the medical consequences of NASH with liver fibrosis or cirrhosis comprises reduction of portal hypertension, reduction in hepatic protein synthetic capability, hyperbilirubinemia, or encephalopathy.

### Claim 12 (depends on 1)

The method of claim 1 wherein administration results in reduction by at least 10% of galectin-3 in liver tissue or serum.

### Claim 13 (depends on 1)

The method of claim 1 wherein in the step of administering the galactomannan polysaccharide is co-administered with an effective amount of a therapeutic agent.

### Claim 14 (depends on 13)

The method of claim 13 wherein the therapeutic agent is one of cysteamine or a pharmaceutically acceptable salt thereof, cystamine or a pharmaceutically acceptable salt thereof, an anti-oxidant compound, lecithin, vitamin B complex, a bile salt preparations, an antagonists of Cannabinoid-1 (CB1) receptor, an inverse agonists of Cannabinoid-1 (CB1) receptor, a peroxisome proliferator-activated receptor) activity regulators, a benzothiazepine or benzothiepine compound, an RNA antisense construct to inhibit protein tyrosine phosphatase PTPRU, a heteroatom-linked substituted piperidine and derivatives thereof, an axacyclopentane derivative, acylamide compound having secretagogue or inducer activity of adiponectin, a quaternary ammonium compound, Glatiramer acetate, pentraxin proteins, a HMG-CoA reductase inhibitor, n-acetyl cysteine, isoflavone compound, a macrolide antibiotic, a galectin inhibitor, an antibody, or any combination of the foregoing.

### Claim 15 (depends on 14)

The method of claim 14 wherein the anti-oxidant compound comprises a water soluble Vitamin E preparation, mixed carotenoids, selenium or combinations thereof.

### Claim 16 (depends on 14)

The method of claim 14 wherein the bile salt preparation comprises ursodeoxycholic acid, chenodeoxycholic acid of naturally occurring bile acids or bile acid salts, chenodeoxycholic acid of synthetic bile acids or bile acid salts or combinations thereof.

### Claim 17 (depends on 14)

The method of claim 14 wherein the prentaxin protein is a recombinant pentraxin-2.

### Claim 18 (depends on 14)

The method of claim 14 wherein the HMG-CoA reductase inhibitors comprises atorvastatin, simvastatin or combinations thereof.

### Claim 19 (depends on 14)

The method of claim 14 wherein the galectin inhibitor comprises small organic inhibitors of galectin, monoclonal antibodies, RNA inhibitors, small binding peptides, protein inhibitors or combinations thereof.

### Claim 20 (depends on 14)

The method of claim 14 wherein the antibody is an antibody against lysyl oxidase or an antibody against connective tissue growth factor.

### Claim 21 (depends on 1)

The method of claim 1 wherein in the step of obtaining the galactomannan polysaccharide has a mannose to galactose ratio ranging from 1:1 to 1:4.

### Claim 22 (depends on 1)

The method of claim 1 wherein in the step of obtaining the galactomannan polysaccharide has a mannose to galactose ratio of 1.7:1.

### Claim 23 (depends on 1)

The method of claim 1 wherein in the step of obtaining the galactomannan polysaccharide has a molecular weight of about 48,000 D.

### Claim 24 (depends on 1)

The method of claim 1 wherein in the step of obtaining the galactomannan polysaccharide has an average molecular weight ranging from 4,000 D to 60,000 D.

### Claim 25

A composition having a galactomannan polysaccharide for the treatment of fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, or nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma.

### Claim 26 (depends on 25)

The composition of claim 25 wherein the galactomannan polysaccharide has a ratio of mannose to galactose of 1.7:1.

### Claim 27 (depends on 25)

The composition of claim 25 wherein the galactomannan polysaccharide has an average molecular weight ranging from 4,000 to 60,000 D.

### Claim 28

Use of a galactomannan polysaccharide in the manufacture of a pharmaceutical composition for the treatment of fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, or nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma.

### Claim 29 (depends on 28)

The use of claim 28 wherein the galactomannan polysaccharide has a ratio of mannose to galactose of 1.7:1.

### Claim 30 (depends on 28)

The use of claim 28 wherein the galactomannan polysaccharide has an average molecular weight ranging from 4,000 to 60,000 D.

### Claim 31

An admixture having a galactomannan polysaccharide and a therapeutic agent for the treatment of fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, or nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma.

### Claim 32

Use of an admixture having a galactomannan polysaccharide and a therapeutic agent in a pharmaceutically acceptable carrier in the manufacture of a pharmaceutical composition for the treatment of fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, or nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma.

### Claim 33 (depends on 31)

The admixture of claim 31 wherein the therapeutic agent is one of cysteamine or a pharmaceutically acceptable salt thereof, cystamine or a pharmaceutically acceptable salt thereof, an anti-oxidant compound, lecithin, vitamin B complex, a bile salt preparations, an antagonists of Cannabinoid-1 (CB1) receptor, an inverse agonists of Cannabinoid-1 (CB1) receptor, a peroxisome proliferator-activated receptor) activity regulators, a benzothiazepine or benzothiepine compound, an RNA antisense construct to inhibit protein tyrosine phosphatase PTPRU, a heteroatom-linked substituted piperidine and derivatives thereof, an axacyclopentane derivative, acylamide compound having secretagogue or inducer activity of adiponectin, a quaternary ammonium compound, Glatiramer acetate, pentraxin proteins, a HMG-CoA reductase inhibitor, n-acetyl cysteine, isoflavone compound, a macrolide antibiotic, a galectin inhibitor, an antibody, or any combination of the foregoing.

### Claim 34 (depends on 31)

The admixture of claim 31 wherein the galactomannan polysaccharide has a ratio of mannose to galactose of 1.7:1.

### Claim 35 (depends on 31)

The admixture of claim 31 wherein the galactomannan polysaccharide has an average molecular weight ranging from 4,000 to 60,000 D.
